After finishing at $3.30 in the prior trading day, Emergent Biosolutions Inc (NYSE: EBS) closed at $3.20, down -3.03%. In other words, the price has decreased by -$0.1000 from its previous closing price. On the day, 4591818 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of EBS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 1.07. In the meantime, Its Debt-to-Equity ratio is 1.26 whereas as Long-Term Debt/Eq ratio is at 0.66.
The Benchmark Company Upgraded its Hold to Buy on April 10, 2023, while the target price for the stock was maintained at $22.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 02 when Zoon Kathryn C sold 1,830 shares for $8.35 per share. The transaction valued at 15,280 led to the insider holds 49,971 shares of the business.
Zoon Kathryn C sold 1,700 shares of EBS for $14,246 on May 25. The Director now owns 51,801 shares after completing the transaction at $8.38 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 166.03M and an Enterprise Value of 940.03M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.15 while its Price-to-Book (P/B) ratio in mrq is 0.24. Its current Enterprise Value per Revenue stands at 0.87 whereas that against EBITDA is -1.77.
Stock Price History:
The Beta on a monthly basis for EBS is 1.21, which has changed by -72.06% over the last 52 weeks, in comparison to a change of 27.55% over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.67, while it has fallen to a 52-week low of $1.42. The 50-Day Moving Average of the stock is 2.0834, while the 200-Day Moving Average is calculated to be 4.3717.
Shares Statistics:
The stock has traded on average 2.87M shares per day over the past 3-months and 10.57M shares per day over the last 10 days, according to various share statistics. A total of 50.10M shares are outstanding, with a floating share count of 49.75M. Insiders hold about 4.12% of the company’s shares, while institutions hold 79.36% stake in the company. Shares short for EBS as of Feb 15, 2024 were 11.54M with a Short Ratio of 4.02, compared to 11.82M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 22.23% and a Short% of Float of 36.82%.
Earnings Estimates
Its stock is currently analyzed by 3 different market analysts. On average, analysts expect EPS of -$0.19 for the current quarter, with a high estimate of $0.07 and a low estimate of -$0.33, while EPS last year was -$0.31. The consensus estimate for the next quarter is -$0.22, with high estimates of -$0.03 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$4.67 and -$5.07 for the fiscal current year, implying an average EPS of -$4.87. EPS for the following year is $1.54, with 2 analysts recommending between $2.51 and $0.57.
Revenue Estimates
3 analysts predict $293.53M in revenue for the current quarter. It ranges from a high estimate of $332.6M to a low estimate of $248M. As of the current estimate, Emergent Biosolutions Inc’s year-ago sales were $330.7M, an estimated decrease of -11.20% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.11B, while the lowest revenue estimate was $1.02B, resulting in an average revenue estimate of $1.07B. In the same quarter a year ago, actual revenue was $1.12B, down -4.80% from the average estimate. Based on 2 analysts’ estimates, the company’s revenue will be $1.18B in the next fiscal year. The high estimate is $1.19B and the low estimate is $1.17B. The average revenue growth estimate for next year is up 11.00% from the average revenue estimate for this year.
